gastric cancer
Conditions
Interventions
2course of capecitabine/oxaliplatin
Sponsors
Kobe City Medical Center General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)histlogically proven gastric adenocarcinoma 2)Clinical T4, or T3 disease in cases of tumors invading the esophagus or of the schirrhous type including giant type 3 with a maximal diameter of more than 8 cm, bulky N2 confirmed by abdominal CT and laparoscopy. The T and N stages are determined according to the method proposed by Haberrmann. 3)Curative resection possible by total body computed tomography (CT) scan 4)Performance status must be Eastern Cooperative Oncology Group (ECOG) 0, or 1 5)Age >= 20 years 6)Patients who can take medication orally 7)Adequate bone marrow, hepatic, renal, cardiac and respiratory functions 8)Written informed consent
Exclusion criteria
Exclusion criteria: 1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) systemic steroid user 5) diabetes mellitus, uncontrolled or controlled with insulin 6) history of myocardial infarction, unstable angina within 3 months prior to the registration 7) serious coexisting illness 8) active infection 9) peripheral neuropathy greater than Grade 2 10) ileus 11) massive pleural effusion or ascites
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactHironaga Satake
Kobe City Medical Center General Hospital Division of Oncology / Gastroenterology,
Outcome results
None listed